Akash Tewari
Stock Analyst at Jefferies
(2.09)
# 2,747
Out of 4,712 analysts
59
Total ratings
36.36%
Success rate
-2.17%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $63 → $70 | $57.68 | +21.36% | 3 | Dec 16, 2024 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $66.89 | +42.02% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $113.95 | +31.64% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $4.36 | +266.97% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $139.44 | +35.54% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $32.68 | +144.80% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $35.91 | +108.86% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $994 → $1,015 | $783.17 | +29.60% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $29.55 | +69.20% | 6 | Apr 9, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $37 → $75 | $45.81 | +63.72% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $23.67 | +30.97% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $32 → $40 | $19.00 | +110.53% | 2 | Dec 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $712.40 | +31.53% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $3.25 | +269.23% | 2 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.64 | +46.42% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $6.01 | +199.50% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $626.31 | -18.09% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.77 | +211.96% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $99.70 | +25.38% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $14.50 | -24.14% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $10.26 | -64.91% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $5.92 | +187.16% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $47.36 | +58.36% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $313.11 | -51.77% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $33.81 | -17.18% | 3 | Oct 7, 2021 |
Bristol-Myers Squibb Company
Dec 16, 2024
Upgrades: Buy
Price Target: $63 → $70
Current: $57.68
Upside: +21.36%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $66.89
Upside: +42.02%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $113.95
Upside: +31.64%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $4.36
Upside: +266.97%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $139.44
Upside: +35.54%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $32.68
Upside: +144.80%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $35.91
Upside: +108.86%
Eli Lilly
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $783.17
Upside: +29.60%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $29.55
Upside: +69.20%
Apogee Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $45.81
Upside: +63.72%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $23.67
Upside: +30.97%
Dec 6, 2023
Upgrades: Buy
Price Target: $32 → $40
Current: $19.00
Upside: +110.53%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $712.40
Upside: +31.53%
Nov 28, 2023
Maintains: Buy
Price Target: $15 → $12
Current: $3.25
Upside: +269.23%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.64
Upside: +46.42%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $6.01
Upside: +199.50%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $626.31
Upside: -18.09%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $5.77
Upside: +211.96%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $99.70
Upside: +25.38%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $14.50
Upside: -24.14%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $10.26
Upside: -64.91%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $5.92
Upside: +187.16%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $47.36
Upside: +58.36%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $313.11
Upside: -51.77%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $33.81
Upside: -17.18%